Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,435,490
  • Shares Outstanding, K 154,543
  • Annual Sales, $ 233,660 K
  • Annual Income, $ 12,670 K
  • 60-Month Beta 2.21
  • Price/Sales 14.70
  • Price/Cash Flow 255.99
  • Price/Book 19.48
Trade TGTX with:

Options Overview Details

View History
  • Implied Volatility 77.41% ( +0.62%)
  • Historical Volatility 41.09%
  • IV Percentile 35%
  • IV Rank 54.04%
  • IV High 134.65% on 01/24/24
  • IV Low 10.10% on 06/10/24
  • Put/Call Vol Ratio 0.49
  • Today's Volume 3,744
  • Volume Avg (30-Day) 4,845
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 102,605
  • Open Int (30-Day) 114,218

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.03
  • Number of Estimates 4
  • High Estimate 0.04
  • Low Estimate 0.02
  • Prior Year 0.73
  • Growth Rate Est. (year over year) -95.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.11 +5.31%
on 09/06/24
26.41 -15.83%
on 09/18/24
+0.15 (+0.68%)
since 09/04/24
3-Month
16.65 +33.51%
on 08/05/24
26.41 -15.83%
on 09/18/24
+3.44 (+18.31%)
since 07/03/24
52-Week
6.46 +244.12%
on 10/16/23
26.41 -15.83%
on 09/18/24
+14.48 (+186.84%)
since 10/04/23

Most Recent Stories

More News
TG Therapeutics: Q2 Earnings Snapshot

TG Therapeutics: Q2 Earnings Snapshot

TGTX : 22.23 (+0.18%)
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

Our first-ever twin bill.

AAPL : 226.80 (+0.50%)
QCOM : 168.90 (-0.01%)
AMZN : 186.51 (+2.50%)
MNKD : 6.49 (+1.09%)
SNBR : 18.25 (+6.48%)
MANH : 282.41 (+1.85%)
TGTX : 22.23 (+0.18%)
QRVO : 102.00 (+0.31%)
ZM : 68.66 (+2.16%)
WOOF : 5.38 (-2.89%)
VZ : 44.18 (-0.76%)
MCD : 303.76 (+0.10%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END

TLSA : 1.0000 (+1.65%)
LLY : 887.16 (+0.18%)
RHHBY : 37.7700 (-1.33%)
BIIB : 185.68 (+0.49%)
TGTX : 22.23 (+0.18%)
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises

TLSA : 1.0000 (+1.65%)
LLY : 887.16 (+0.18%)
RHHBY : 37.7700 (-1.33%)
BIIB : 185.68 (+0.49%)
TGTX : 22.23 (+0.18%)
Why TG Therapeutics Stock Was Rocketing Higher This Week

The company raised guidance for sales of its drug for relapsing multiple sclerosis.

TGTX : 22.23 (+0.18%)
TG Therapeutics: Q1 Earnings Snapshot

TG Therapeutics: Q1 Earnings Snapshot

TGTX : 22.23 (+0.18%)
TG Therapeutics: Q4 Earnings Snapshot

TG Therapeutics: Q4 Earnings Snapshot

TGTX : 22.23 (+0.18%)
Why TG Therapeutics Stock Is Crushing It Today

The biopharmaceutical company's Q3 update was music to investors' ears.

TGTX : 22.23 (+0.18%)
TG Therapeutics: Q3 Earnings Snapshot

TG Therapeutics: Q3 Earnings Snapshot

TGTX : 22.23 (+0.18%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX). Such...

TGTX : 22.23 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 23.88
2nd Resistance Point 23.32
1st Resistance Point 22.77
Last Price 22.23
1st Support Level 21.66
2nd Support Level 21.10
3rd Support Level 20.55

See More

52-Week High 26.41
Last Price 22.23
Fibonacci 61.8% 18.79
Fibonacci 50% 16.43
Fibonacci 38.2% 14.08
52-Week Low 6.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar